Freenome swings to Q3 net profit of $60.11 million; Q3 revenue rises to $183.49 million
ABT•Freenome reported third-quarter 2026 net income of $60.1 million and revenue of $183.5 million, driven primarily by collaboration payments after FDA approval of SimpleScreen CRC. It expects full-year revenue of $192 million to $194 million.
1. Quarterly results
Freenome swung to GAAP net income of $60.1 million in the third quarter of 2026 from a year-earlier loss, while revenue rose to $183.5 million. The company said collaboration payments following FDA approval of SimpleScreen CRC primarily drove the increase.
2. Product launch and outlook
Abbott launched SimpleScreen CRC in the United States on September 30, 2026, under a commercial license agreement. Freenome expects full-year 2026 revenue of $192 million to $194 million.
